The New Paper

April 1, 2021

Johnson and Johnson announces issues with vaccine supplier

Johnson & Johnson announced that a batch of partially-completed coronavirus vaccines made by Emergent Biosolutions did not meet quality standards. The doses (reportedly in the range of ~15M) did not reach the fill-and-finish stage of production, and J&J noted that it remains on track to deliver 100M doses by the end of May. Here’s the full statement.
This story is from the April 1, 2021 edition of The New Paper – a clear, concise daily briefing that makes fact-first news easy to consume. Try it today.